Is Merck Hanging Schering Out to Dry on Vytorin?VytorinPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and Merck...
By Bill Berkrot and Ransdell Pierson NEW YORK (Reuters) - The cholesterol fighter Vytorin sold by Merck & Co Inc MRK and Schering-Plough Corp SGP failed to meet the main goal of improving outcomes in a closely-watched heart study, according to data presented...
By Lewis Krauskopf and Ransdell Pierson NEW YORK (Reuters) - Merck & Co Inc MRK cut its sales outlook on two key medicines on Monday and indicated its financial forecasts were in doubt after a mostly negative study of cholesterol treatment Vytorin, sending...
NEW YORK (Reuters) - Merck & Co MRK and Schering-Plough SGP said they would delay release of company earnings until after the stock market closes on Monday, in order to update investors on a new important study of their shared Vytorin ...
Schering-Plough Now in the Feds' CrosshairsThe Great Disappointment of EthicsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and...
How Pharma Stacks the Deck with Medical JournalsStatistical GymnasticsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and Merck...
The Vytorin scandal just got serious. Well, heck, it was already serious. Make this really serious: Investigation and Inquiries. Through the date of filing this 10-Q, Schering-Plough, the joint venture and/or its ...
A close reading of the Merck and Schering-Plough first-quarter conference calls suggests that Merck is distancing itself from its joint-venture partner -- who is, in any event, in a much worse position to weather the storm over their cholesterol-fighting pill Vytorin. Vytorin, of course, is a combination...
As an example of how not to handle a corporate crisis, it's hard to beat the growing scandal over Vytorin. That's the blockbuster anti-cholesterol drug whose clinical-trial data Merck and Schering-Plough sat on for a year or two after it showed that Vytorin was apparently no better than a...
The saga over Vytorin, the expensive cholesterol pill that may be no better than older, cheaper "statin" drugs, has come to a familiar pass: The manufacturer backlash. Merck and Schering-Plough, the makers of Vytorin, saw their stocks crushed the day after cardiologists trashed the multi-billion-dollar drug at...
The saga over Vytorin, the expensive cholesterol pill that may be no better than older, cheaper "statin" drugs, has come to a familiar pass: The manufacturer backlash. Merck and Schering-Plough, the makers of Vytorin, saw their stocks crushed the day after cardiologists trashed the multi-billion-dollar drug at...
In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/4e90d7/vytorin_wave_two) has announced the addition of the "Vytorin: Wave Two - Impact of ENHANCE Trial" report to their offering. A Survey of One-Hundred Three US-based PCP's and Cardiologists Deliverable: Survey with key findings. Study Description: Topic:...
RADNOR, Pa., June 19 /PRNewswire/ -- ADVERTISEMENT - The following statement was issued today by the law firm of Schiffrin Barroway Topaz & Kessler, LLP: Schiffrin Barroway Topaz & Kessler, LLP is Co-Lead Counsel for the ERISA plaintiffs in the In re Merck & Co. Inc. Securities,...
CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Merck (NYSE: MRK), Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA), Eastman Chemical (NYSE:...
Lawsuit claims manufacturers misled consumers about the use of Zetia and Vytorin. SEATTLE, June 10 /PRNewswire/ -- Last week the U.S. District Court in New Jersey appointed Hagens Berman, along with four other firms, co-counsel in a case against Schering-Plough and Merck which claims the...
Harte-Hanks has announced plans to close a New Jersey office, one of its 30 company locations nationwide. Jobs lost in the shuffle represented less than 1% of the company's 7,100 employee base, says Doug Shepard, CFO. Tasks performed at the New Jersey facility have been shifted to other locations. ...
Several factors continue to make a case for the economy of PR. First, the ROI of a PR campaign compared to its advertising counterpart remains unchallenged. Even the most expensive national public relations campaign is small marketing peanuts compared to consumer advertising. PR can deliver both as part of...
Jami Rubin Morgan Stanley Stock: Schering-Plough Price target $20.00 Share price (as of April 4,2008) $16.12 52-Week Range $33.81-13.83 Significant stock sell-off for both Schering-Plough (-25%) and Merck (-15%) after the American College of Cardiology ACC conference thus far looks drastically disproportionate to the...
